OSR Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $3.19 million, a slight improvement from a net loss of $3.36 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $19.81 million, compared to a loss of $8.99 million for the same period in 2024. The company's revenue for the third quarter was $627,747, down 24% from $822,996 in the prior year, while year-to-date revenue decreased by 3% to $2.52 million from $2.62 million.
The decline in revenue was attributed to a strategic shift in the business model of its subsidiary, RMC, which transitioned from a traditional purchase-and-resale model to a consignment-based arrangement. This change, effective from July 2025, is expected to stabilize gross margins in the future. Despite the drop in sales, gross profit for the third quarter increased by 46% to $261,734, driven by a significant reduction in the cost of sales, which fell by 43% to $366,014.
OSR Holdings has undergone significant organizational changes, including the completion of a business combination with OSR Holdings Co., Ltd. in February 2025, which has led to increased operational costs. Selling, general, and administrative expenses rose by 9% in the third quarter and 16% year-to-date, primarily due to higher personnel-related costs and professional service fees. The company also reported a substantial increase in other expenses, largely due to one-time merger-related costs amounting to approximately $8.5 million.
As of September 30, 2025, OSR Holdings had total assets of $177.29 million, a slight increase from $175.24 million at the end of 2024. The company’s cash and cash equivalents rose significantly to $2.18 million from $341,543 at the end of the previous year. However, total liabilities increased to $43.13 million from $32.03 million, reflecting higher short-term borrowings and trade payables. The company’s accumulated deficit also widened to $32.33 million.
Looking ahead, OSR Holdings is focused on leveraging its recent business combination to enhance its product development and commercialization efforts. The company is actively exploring various financing initiatives, including an equity line of credit, to support its operations and growth strategy. Management is also monitoring its compliance with Nasdaq listing requirements, as the company received a deficiency notice regarding its share price. The company aims to regain compliance by implementing strategic measures to enhance shareholder value.
About OSR Holdings, Inc.
OSR Holdings, Inc. is a global healthcare holding company operating through subsidiaries focused on developing innovative therapies and medical devices. Its core businesses include oral T-cell immunotherapies for cancer, design-augmented biologics for age-related degenerative diseases, and neurovascular intervention device distribution in Korea. OSR leverages scientific expertise and strategic partnerships to advance drug development and commercialization, targeting unmet medical needs with a diversified, risk-managed portfolio across major healthcare markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.